Editas Medicine (EDIT) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free EDIT Stock Alerts $5.22 -0.13 (-2.43%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEditas to present gene editing advancements at ASGCTinvesting.com - April 24 at 8:00 PMFinancial Analysis: Editas Medicine (NASDAQ:EDIT) vs. Outlook Therapeutics (NASDAQ:OTLK)americanbankingnews.com - April 23 at 1:54 AMEditas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meetingglobenewswire.com - April 22 at 4:31 PMEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Brokeragesamericanbankingnews.com - April 21 at 2:44 AMMirae Asset Global Investments Co. Ltd. Sells 177,556 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - April 20 at 4:54 AMEditas Medicine Inc (EDIT)investing.com - April 18 at 12:22 PMEditas Medicine (NASDAQ:EDIT) Hits New 52-Week Low at $6.05marketbeat.com - April 15 at 3:58 PMEditas Medicine, Inc. (NASDAQ:EDIT) Short Interest Updatemarketbeat.com - April 14 at 2:55 PMInternational Assets Investment Management LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - April 10 at 5:08 AMDr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officerfinance.yahoo.com - April 9 at 8:23 AMVanguard Group Inc. Has $66.58 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - April 8 at 4:08 AMEditas Medicine, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.85) Per Share (NASDAQ:EDIT)marketbeat.com - March 22 at 7:49 AMEditas Medicine, Inc. Forecasted to Earn FY2026 Earnings of ($2.80) Per Share (NASDAQ:EDIT)marketbeat.com - March 21 at 8:36 AMShort Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 7.4%marketbeat.com - March 18 at 7:26 PMEditas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)seekingalpha.com - March 13 at 7:58 PMEditas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)seekingalpha.com - March 12 at 3:56 PM1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.fool.com - March 7 at 3:31 AMEditas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)seekingalpha.com - March 6 at 5:05 PM1 Beaten-Down Stock With 55% Upside, According to Wall Streetfool.com - March 4 at 10:30 AMTrexquant Investment LP Purchases 107,776 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - March 4 at 6:37 AMWhy Editas Medicine Stock Soared as Much as 42% Higher This Weekfool.com - March 2 at 9:49 PMEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analystsmarketbeat.com - March 2 at 2:14 AMStrong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimismmarkets.businessinsider.com - March 1 at 10:17 AMHold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation Potentialmarkets.businessinsider.com - February 29 at 1:51 PMEditas Medicine (NASDAQ:EDIT) Price Target Raised to $16.00 at Citigroupmarketbeat.com - February 29 at 12:44 PMQ4 2023 Editas Medicine Inc Earnings Callfinance.yahoo.com - February 29 at 1:24 AMEditas Medicine files for mixed shelf offeringmsn.com - February 28 at 8:23 PMEditas Medicine Shares Rally After Reni-cel Study Upgrademarketwatch.com - February 28 at 3:23 PMEditas Medicine (NASDAQ:EDIT) Shares Gap Up on Analyst Upgrademarketbeat.com - February 28 at 10:25 AMEditas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32Mmsn.com - February 28 at 10:22 AMHere's what Wall Street expects from Editas Medicine's earnings reportmarkets.businessinsider.com - February 28 at 10:22 AMEditas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trialsfinance.yahoo.com - February 28 at 10:22 AMEditas spikes as Vertex Pharma deal boosts Q4 toplinemsn.com - February 28 at 10:22 AMEditas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updatesglobenewswire.com - February 28 at 7:00 AMEarnings Outlook For Editas Medicinebenzinga.com - February 27 at 1:51 PMEditas Medicine Q4 2023 Earnings Previewmsn.com - February 27 at 1:51 PMHealthcare of Ontario Pension Plan Trust Fund Takes $944,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - February 27 at 6:37 AMEDIT Mar 2024 7.000 putfinance.yahoo.com - February 24 at 11:13 AMEDIT Mar 2024 12.000 callca.finance.yahoo.com - February 24 at 6:12 AMQRG Capital Management Inc. Invests $635,000 in Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - February 23 at 6:20 AMEditas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Eventsglobenewswire.com - February 21 at 7:00 AMRafferty Asset Management LLC Sells 80,327 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - February 20 at 6:53 AMWall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Tradefinance.yahoo.com - February 19 at 1:14 PMEditas Medicine, Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)seekingalpha.com - February 13 at 1:14 PMTwo GV partners on biotech’s reset and building their next drug startupsfinance.yahoo.com - February 13 at 9:35 AMNASDAQ:EDIT (Editas Medicine)fool.ca - February 12 at 8:32 AMEditas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)seekingalpha.com - February 7 at 2:00 PMEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analystsmarketbeat.com - February 6 at 2:13 AMEditas Medicine to Participate in Upcoming Investor Conferencesfinance.yahoo.com - January 31 at 1:59 PMEditas Medicine (NASDAQ:EDIT) shareholders have endured a 87% loss from investing in the stock three years agofinance.yahoo.com - January 25 at 10:21 AM Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide EDIT Media Mentions By Week EDIT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼0.310.37▲Average Medical News Sentiment EDIT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼63▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Taysha Gene Therapies News Today C4 Therapeutics News Today Tourmaline Bio News Today Alector News Today Exscientia News Today Replimune Group News Today Voyager Therapeutics News Today Fate Therapeutics News Today Mesoblast News Today Ocugen News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
